Zacks Investment Research
18 Aug 2026, 16:51 UTC · 1h ago
MESO Completes Patient Treatment in Chronic Back Pain Study, Stock Up
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
18 Aug 2026, 16:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Mesoblast's candidate rexlemestrocel-L for chronic low back pain has a potential peak annual revenue opportunity exceeding $10 billion. — The scale of the potential revenue relative to a small-cap biotech represents a massive fundamental valuation driver if successful.
+0.80Mesoblast has completed patient treatment in its pivotal phase III MSB-DR004 study for chronic low back pain. — Completing treatment is a key operational milestone that moves the company closer to clinical data readout.
+0.40The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to rexlemestrocel-L, potentially enabling priority review. — RMAT designation reduces regulatory timelines and increases the probability of a faster path to market.
+0.30Continue reading
6 related stories
Search tags
Top-line data from the phase III study is not expected until mid-2027. — The distant date for data readout creates a long period of uncertainty and delays the realization of the aforementioned revenue potential.
-0.20Which stocks this story touches
Completed patient treatment in a pivotal phase III study for chronic low back pain, which is seen as a major milestone and growth opportunity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
6h ago
